However, at late stages (when mice developed signs and symptoms of advanced tumor growth; about 3–4 weeks for control mice and 5–7 weeks for bevacizumab-treated mice), tumors progressed and HIG2 expression was upregulated (Figure 6D–6E). The gene discussed is HILPDA; the disease is neoplasm.